Skip to main content
. 2025 Aug 6;29(10):100648. doi: 10.1016/j.jnha.2025.100648

Table 3.

Association of individual components of physical frailty with risk of incident degenerative AS and AS-related events.

Physical frailty components HR (95% CI)
Model 1 a Model 2 b Model 3 c
AS
 Weight loss 1.38 (1.29−1.47) 1.29 (1.21−1.38) 1.30 (1.21−1.39)
 Exhaustion 1.54 (1.43−1.66) 1.22 (1.13−1.32) 1.16 (1.07−1.25)
 Low physical activity 1.46 (1.35−1.58) 1.12 (1.04−1.21) 1.04 (0.96−1.12)
 Slow gait speed 2.19 (2.04−2.35) 1.37 (1.27−1.47) 1.30 (1.21−1.41)
 Low grip strength 1.46 (1.39−1.55) 1.20 (1.14−1.27) 1.18 (1.11−1.25)
AS-related events
 Weight loss 1.28 (1.15−1.43) 1.22 (1.09−1.35) 1.22 (1.10−1.36)
 Exhaustion 1.39 (1.23−1.57) 1.14 (1.01−1.29) 1.10 (0.97−1.24)
 Low physical activity 1.44 (1.28−1.62) 1.15 (1.02−1.30) 1.10 (0.97−1.24)
 Slow gait speed 1.85 (1.65−2.07) 1.23 (1.09−1.39) 1.16 (1.02−1.31)
 Low grip strength 1.46 (1.34−1.58) 1.24 (1.14−1.35) 1.23 (1.12−1.34)

HR, hazard ratio; CI, confidence interval; AS, aortic valve stenosis.

a

Model 1 adjusted for age, sex, race, UK Biobank assessment center, Townsend deprivation index, education, smoking status, alcohol consumption status, healthy diet score, and sleep duration.

b

Model 2 included model 1 plus body mass index, systolic blood pressure, glycated haemoglobin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate, C-reactive protein, coronary heart disease, atrial fibrillation, stroke, chronic obstructive pulmonary disease, osteoporosis, chronic inflammatory disease, antihypertensive medication, antidiabetic medication, lipid-lowering medication, and antiplatelet medication.

c

Model 3 included model 2 plus five frailty components (mutual adjustment).